Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDV and HAV Vaccine Co-administration in Healthy Adults
NCT03525119Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in dengue fever comparing HAV Vaccine + Placebo, TDV + Placebo and TDV + HAV Vaccine (3 arms). Primary endpoint: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30. Started May 2018; status: completed.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03525119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525119.